The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.
March 12th 2025
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.